1. Home
  2. AIRE vs KPRX Comparison

AIRE vs KPRX Comparison

Compare AIRE & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$1.48

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.54

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRE
KPRX
Founded
2021
1998
Country
United States
United States
Employees
N/A
13
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
11.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
AIRE
KPRX
Price
$1.48
$2.54
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$1.30
$10.00
AVG Volume (30 Days)
44.0K
19.6K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
60.34
N/A
EPS
N/A
N/A
Revenue
$4,518,498.00
N/A
Revenue This Year
$129.06
N/A
Revenue Next Year
$83.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
376.42
N/A
52 Week Low
$0.16
$1.76
52 Week High
$3.98
$3.23

Technical Indicators

Market Signals
Indicator
AIRE
KPRX
Relative Strength Index (RSI) 30.96 56.29
Support Level $0.29 $2.44
Resistance Level $2.17 $2.72
Average True Range (ATR) 0.16 0.09
MACD -0.06 0.00
Stochastic Oscillator 0.00 64.52

Price Performance

Historical Comparison
AIRE
KPRX

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: